S
Shenping Liu
Researcher at Pfizer
Publications - 43
Citations - 1866
Shenping Liu is an academic researcher from Pfizer. The author has contributed to research in topics: Glucokinase & Binding site. The author has an hindex of 22, co-authored 41 publications receiving 1598 citations.
Papers
More filters
Journal ArticleDOI
1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.
Kim M. Andrews,David A. Beebe,John William Benbow,David A. Boyer,Shawn D. Doran,Yu Hui,Shenping Liu,R. Kirk McPherson,Constantin Neagu,Janice C. Parker,David W. Piotrowski,Steven R. Schneider,Judith L. Treadway,Maria A. VanVolkenberg,William James Zembrowski +14 more
TL;DR: The addition of a gem-difluoro substituent to the lactam improved overall DPP-4 inhibition and an efficient asymmetric route to 3,4-diaminopyrrolidines was developed.
Journal ArticleDOI
Ligand–Protein Interactions of Selective Casein Kinase 1δ Inhibitors
Scot Richard Mente,Eric P. Arnold,Butler Todd W,Subramanyam Chakrapani,Ramalakshmi Yegna Chandrasekaran,Kevin Cherry,Ken Dirico,Angela C. Doran,Katherine Fisher,Paul Galatsis,Michael Eric Green,Matthew Merrill Hayward,John M. Humphrey,John D. Knafels,Jianke Li,Shenping Liu,Michael Marconi,W. Scott McDonald,Jeff Ohren,Vanessa Paradis,Blossom Sneed,Kevin M. Walton,Travis T. Wager +22 more
TL;DR: In vivo evaluation of a series of pyrazole-substitued pyridine inhibitors demonstrates that selective inhibition of CK1δ at sufficient central exposure levels is capable of modulating circadian rhythms.
Journal ArticleDOI
Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA).
Ariamala Gopalsamy,Arjun Narayanan,Shenping Liu,Mihir D. Parikh,Robert E. Kyne,Olugbeminiyi O. Fadeyi,Michael A. Tones,Jonathan J. Cherry,Joseph F. Nabhan,Gregory LaRosa,Donna N. Petersen,Carol A. Menard,Timothy L. Foley,Stephen Noell,Yong Ren,Paula M. Loria,Jodi Maglich-Goodwin,Haojing Rong,Lyn H. Jones +18 more
TL;DR: The design, synthesis, and in vitro pharmacological characterization of these DcpS inhibitors are described along with the in vivo mouse CNS PK profile of PF-DcpSi (compound 24), one of the analogs found to be efficacious in SMA mouse model.
Journal ArticleDOI
Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors
Travis T. Wager,Paul Galatsis,Ramalakshmi Yegna Chandrasekaran,Butler Todd W,Jianke Li,Lei Zhang,Scot Richard Mente,Chakrapani Subramanyam,Shenping Liu,Angela C. Doran,Cheng Chang,Katherine Fisher,Sarah Grimwood,Joseph R. Hedde,Michael Marconi,Klaas Schildknegt +15 more
TL;DR: This effort investigated the possibility of developing a CNS positron emission tomography (PET) radioligand and identified [3H]PF-5236216 (9) as a tool ligand that meets most of the key CNS PET attributes including high CNS MPO PET desirability score and kinase selectivity, CNS penetration, and low nonspecific binding.
Journal ArticleDOI
An Intracellular Allosteric Modulator Binding Pocket in SK2 Ion Channels Is Shared by Multiple Chemotypes.
Lily T. Y. Cho,Aristos J. Alexandrou,Rubben Torella,John D. Knafels,Jake Hobbs,Toni Taylor,Alexandre J.C. Loucif,Agnieszka Konopacka,Sigourney Bell,Edward B. Stevens,Jay Pandit,Reto Horst,Jane M. Withka,David C. Pryde,Shenping Liu,Gareth T. Young +15 more
TL;DR: A binding pocket situated at the intracellular interface of SK2 and calmodulin is characterized, which it is shown to be shared by multiple small-molecule chemotypes and to define a clinically important site, laying the foundations for further studies of the mechanism of action of riluzole and related molecules.